All resources

Access to Medicine • August 20, 2020

IMC and BTC joint response to CADTH’s transparency consultation

IMC and and BIOTECanada write to Suzanne McGurn with joint input on the current CADTH process consultation….

Learn more | View

February 18, 2019

Pan-Canadian Pharmaceutical Alliance (pCPA): Timelines Analysis and Policy Implications (February 2019)

Learn more | View

April 28, 2022

Reflections on a Potential Pan-Canadian Drug Formulary: Medicines Industry Response to CADTH Consultation

Learn more | View

March 29, 2019

Factors Influencing Delays in Patient Access to New Medicines in Canada: A Retrospective Study of Reimbursement Processes in Public Drug Plans (March 2019)

Learn more | View

Access to Medicine • August 21, 2023

pCPA Temporary Access Process: Innovative Medicines Industry Consultation Response

Learn more | View

November 01, 2018

Guide to Providing Clinician Input and Feedback with the pCODR Program (2018)

Learn more | View

October 09, 2018

Real World Evidence Workshop: Industry Input – IMC/BIOTECanada Working Group (2018)

Learn more | View

October 01, 2017

Data Analytics and Members’ Economic Footprint and Impact in Canada

Learn more | View

June 30, 2016

Access to New Medicines in Public Drug Plans: Canada and Comparable Countries – 2016 Annual Report

Learn more | View

Pharmacare • June 01, 2023

Addendum to Innovative Medicines Canada Submission on National Pharmacare

Learn more | View

Patented Medicine Prices Review Board (PMPRB) • August 04, 2020

IMC Response to PMPRB 2020 Draft Guidelines

Learn more | View

Access to Medicine • May 06, 2025

Canadian Drug Access Pathway

Learn more | View